Goodsurance
ES

Drug prices & Part D

Medicare Sent Its Final Drug Price Offers by September 30. Manufacturers Now Have Until October 31 to Respond.

With the statutory September 30 written-offer deadline now passed, each manufacturer whose drug is in Medicare's third negotiation cycle must accept or reject CMS's maximum fair price offer in writing by October 31, closing the formal negotiation period.

By the Goodsurance editorial teamOctober 1, 2026

The Centers for Medicare and Medicaid Services met the statutory September 30, 2026, deadline to send final maximum fair price written offers to the manufacturers of all 15 drugs selected for the third cycle of Medicare drug price negotiations. Each manufacturer must now accept or reject the offer in writing by October 31, 2026.

The 15 drugs span a range of conditions, including HIV, rheumatoid arthritis, inflammatory bowel disease, prostate cancer, breast cancer, and diabetes. Several of the selected drugs are covered under Medicare Part D, meaning patients pick them up at a pharmacy. Others are Part B drugs administered by a clinician in a doctor's office or infusion center, making this the first negotiation cycle to include physician-administered medicines.

CMS met its September 30 deadline to send final price offers on 15 drugs. Manufacturers have until October 31 to respond. If accepted, prices take effect January 2028.

If a manufacturer accepts the offer, the negotiated price becomes the maximum fair price effective January 1, 2028. If a manufacturer rejects it, CMS sets the maximum fair price unilaterally. Drug companies that then refuse to comply face an excise tax under the Inflation Reduction Act.

All 15 manufacturers had agreed in March 2026 to participate in the negotiation process. Face-to-face talks ran through September 11, and both sides could exchange written counteroffers through September 18 before CMS sent its final offer. October 31 is the last date manufacturers may formally respond, after which the negotiation period closes on November 1.

Negotiated prices from earlier cycles already reduced out-of-pocket costs for certain Medicare enrollees, with first-cycle prices having taken effect January 1, 2026.

In plain words

Medicare has been negotiating prices for 15 prescription drugs this year. By September 30, the government sent its final price offer to each drug company. The drug companies now have until October 31 to say yes or no. If they say yes, the new lower prices will take effect January 1, 2028. If they say no, the government still sets the price. These 15 drugs treat conditions like HIV, arthritis, cancer, and diabetes. This is the third round of Medicare drug price talks, and it is the first round to include drugs given in a doctor's office rather than at a pharmacy.

Source: CMS
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Biotech Industry Group Files Second Lawsuit to Block Medicare's GLOBE Drug Pricing Model

BIO and two California biotech groups sued CMS on November 6, arguing the program exceeds legal authority. A first challenge from PhRMA filed in October remains pending.

November 12, 2026

Drug prices & Part D

KFF: Medicare's 340B Drug Payment Cut Reduces Revenue for Safety-Net Hospitals While Raising It for For-Profit Ones

Now that the 2027 outpatient rule is final, a KFF analysis finds the 340B reimbursement cut falls hardest on hospitals that serve low-income patients, while for-profit hospitals see a net gain.

November 11, 2026

Drug prices & Part D

Medicare Drug Price Negotiation Rules Are Now Permanent, Federal Register Shows

The CMS-4215-F final rule, published today, converts the negotiation program from administrative guidance into binding federal regulation for every drug-price cycle starting in 2029, and requires Part D plans to cover negotiated-price drugs on their formularies.

November 9, 2026

Drug prices & Part D

Third Medicare Drug Negotiation Cycle Closes, Including Part B Doctor-Office Drugs for the First Time

The formal negotiation period for 15 drugs ended November 1; CMS must publish any agreed-upon maximum fair prices by November 30, including the first-ever negotiated prices for drugs given in doctors' offices.

November 1, 2026

Drug prices & Part D

Average Medicare Part D Stand-Alone Premium Projected to Rise 50 Percent for 2027, KFF Finds

A KFF analysis published today finds the average monthly premium for stand-alone Part D drug plans is on track to climb from 34 dollars to 51 dollars for 2027, with deductibles also rising sharply, for enrollees who do not switch plans before December 7.

October 30, 2026

Drug prices & Part D

Study: Medicare Drug Price Negotiations Cut Costs for Most Enrollees, but Not for Those Already Hitting the Annual Spending Limit

A research letter in Annals of Internal Medicine finds that patients on six of the first ten negotiated Part D drugs saw out-of-pocket costs fall 26 to 49 percent, while patients on the three highest-priced negotiated drugs saw no additional benefit because they were already reaching the annual cap.

October 24, 2026